Non Hodgkin Lymphoma: Clinical Trials

156 trials for Non Hodgkin Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

47 completed, 31 recruiting, 29 terminated, 20 unknown. 76 Phase 1, 54 Phase 2, 20 Not applicable, 6 Phase 3, 3 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 176Completed 19, Recruiting 16, Terminated 14, Active not recruiting 13, Unknown 9, Withdrawn 4, Suspended 1
Phase 254Terminated 15, Completed 12, Recruiting 10, Unknown 9, Active not recruiting 6, Withdrawn 2
Not applicable20Completed 7, Terminated 4, Active not recruiting 2, Recruiting 2, Unknown 2, Withdrawn 2, Not yet recruiting 1
Phase 36Completed 4, Terminated 2
Phase 43Completed 2, Recruiting 1
Early Phase 12Not yet recruiting 1, Recruiting 1

Follow Non Hodgkin Lymphoma: new trials by email Literature Review of Non Hodgkin Lymphoma trials Research Report on Non Hodgkin Lymphoma

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies
Ossium HPC, Marrow, Standard of care living donor - Haplo Related, Standard of care living donor - Mismatched Unrelated - Hematologic Malignancy, Acute Leukemia
Not applicableNot yet recruitingOssium Health, Inc.3002026-12-012026-09-10
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Allogeneic NK cells, Rituximab, Tafasitamab - Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma
Phase 1RecruitingPaolo Caimi, MD152026-09-012026-09-09
Pre-malignant States to Hematologic Malignancies in Firefighters
Monoclonal Gammopathy, Complete Blood Count with differential (CBC w/ diff), Clonal hematopoiesis (CHIP) - Clonal Hematopoiesis of Indeterminate Potential, Monoclonal Gammopathy
RecruitingWake Forest University Health Sciences3002026-06-232026-07-13
SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas
SB-4826, Rituximab - Non Hodgkin Lymphoma, Solid Tumor
Phase 1 / Phase 2RecruitingUniversity of California, San Diego482026-02-182026-03-05
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK - Cancer, Breast Cancer
Phase 1 / Phase 2RecruitingEssen Biotech852026-02-012026-02-18
Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford
Neuropsychological testing - Non Hodgkin Lymphoma
Not applicableWithdrawnStanford University2025-12-012026-06-24
A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma.
Omeprazole, Dextromethorphan - Hodgkin Lymphoma, Non Hodgkin Lymphoma
Phase 1RecruitingMurdoch Childrens Research Institute102025-07-222026-08-27
Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy
GOLCADOMIDE, Nivolumab - Non Hodgkin Lymphoma
Phase 1 / Phase 2WithdrawnUniversity of Pittsburgh2025-06-302026-04-13
Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies
Ceftazidime, Ciprofloxacin - Neutropenic Fever, Acute Lymphoblastic Leukemia
Phase 4RecruitingGadjah Mada University1202025-06-012025-08-22
A Study to Evaluate the Safety and Clinical Efficacy of STR-P004
STR-P004 - Non Hodgkin Lymphoma
Early Phase 1Not yet recruitingStarna Therapeutics302025-06-012025-06-04
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101 - B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
Phase 1 / Phase 2RecruitingVironexis Biotherapeutics Inc.322025-05-302026-10-26
IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL
Iomab-B, CAR-T cell - Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Phase 1 / Phase 2RecruitingUniversity of Texas Southwestern Medical Center302025-04-252026-05-08
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Pirtobrutinib, LV20.19 CAR T cells - Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Phase 1RecruitingMedical College of Wisconsin122025-02-062026-08-06
A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
ONO-7018 - Non Hodgkin Lymphoma
Phase 1TerminatedOno Pharmaceutical Co., Ltd.22024-11-272026-07-29
PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy
64Cu-GRIP B, Positron Emission Tomography (PET), Optional tumor biopsy - Non Hodgkin Lymphoma
Phase 1RecruitingMichael Randall322024-10-232025-12-29
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Darzalex Faspro (Daratumumab and hyaluronidase-fihj), JH-DSA Semi-Quant Screen and Response Score - Hematologic Malignancy, Bone Marrow Transplant Rejection
Early Phase 1RecruitingSidney Kimmel Comprehensive Cancer Center at Johns Hopkins82024-09-192026-10-05
Impact of Respiratory Training in Lymphoma Survivors
Inspiratory muscle strength training, Sham Inspiratory muscle strength training - Hodgkin Lymphoma, Non Hodgkin Lymphoma
Not applicableTerminatedUniversity of Colorado, Denver12024-09-162026-02-27
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
Long-term Follow-Up - Non Hodgkin Lymphoma, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
RecruitingMiltenyi Biomedicine GmbH1502024-05-152026-08-05
AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW)
ARROW strategies, One-time education - Cervical Cancer, Kaposi Sarcoma
Not applicableRecruitingImplenomics41002024-05-012026-11-04
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
TGRX-814 - Hematologic Malignancy, Non Hodgkin Lymphoma
Phase 1 / Phase 2RecruitingShenzhen TargetRx Co., Ltd.302024-03-062024-04-10

Showing 20 of 156. Sign in to see all of them.

Narrower conditions

Lymphoma, Non-Hodgkin (156)  ·  Hodgkin Disease (36)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (28)  ·  Leukemia, Myeloid, Acute (26)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (24)  ·  Lymphoma, Follicular (22)  ·  Multiple Myeloma (22)  ·  Lymphoma, Large B-Cell, Diffuse (19)  ·  Myelodysplastic Syndromes (18)  ·  Lymphoma (16)  ·  Lymphoma, B-Cell (16)  ·  Lymphoma, Mantle-Cell (15)  ·  Leukemia (13)  ·  Lymphoma, B-Cell, Marginal Zone (12)  ·  Neoplasms (12)

Broader conditions

Hemic and Lymphatic Diseases (156)  ·  Immune System Diseases (156)  ·  Immunoproliferative Disorders (156)  ·  Lymphatic Diseases (156)  ·  Neoplasms by Histologic Type (156)  ·  Lymphoproliferative Disorders (155)  ·  Neoplasms (144)  ·  Lymphoma (140)  ·  Hematologic Diseases (62)  ·  Leukemia (47)  ·  Pathologic Processes (47)  ·  Pathological Conditions, Signs and Symptoms (47)  ·  Leukemia, Lymphoid (43)  ·  Disease Attributes (39)  ·  Chronic Disease (36)

Interventions

Cyclophosphamide (23)  ·  Rituximab (15)  ·  fludarabine (13)  ·  fludarabine phosphate (8)  ·  Mycophenolic Acid (7)  ·  Bendamustine Hydrochloride (4)  ·  Interleukin-2 (4)  ·  Tacrolimus (4)  ·  Whole-Body Irradiation (4)  ·  acalabrutinib (4)  ·  venetoclax (4)  ·  Azacitidine (3)  ·  Blood Specimen Collection (3)  ·  Cyclosporine (3)  ·  Filgrastim (3)

Sponsors

Wake Forest University Health Sciences (4)  ·  Baylor College of Medicine (3)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3)  ·  Stanford University (3)  ·  University of Colorado, Denver (3)  ·  Ascentage Pharma Group Inc. (2)  ·  Case Comprehensive Cancer Center (2)  ·  Centre Leon Berard (2)  ·  Chongqing Precision Biotech Co., Ltd (2)  ·  Copenhagen University Hospital, Rigshospitalet (2)  ·  David Wald (2)  ·  Fondazione Italiana Linfomi - ETS (2)  ·  Huiqiang Huang (2)  ·  Institut Paoli-Calmettes (2)  ·  MEI Pharma, Inc. (2)

Countries

United States (82)  ·  China (25)  ·  France (21)  ·  Australia (14)  ·  Italy (12)  ·  Spain (11)  ·  United Kingdom (11)  ·  Belgium (9)  ·  Poland (9)  ·  South Korea (6)  ·  Germany (5)  ·  Taiwan (5)  ·  Denmark (4)  ·  Canada (3)  ·  Czechia (3)

Top investigators

Arnon Nagler, MD (2)  ·  Benjamin Tomlinson, MD (2)  ·  Helen E Heslop, MD (2)  ·  Jianxiang Wang, MD (2)  ·  A. Paz Coll, MD (1)  ·  A. Salar, MD (1)  ·  Akhil Kumar, MD (1)  ·  Alessandro Rambaldi, MD (1)  ·  Amir A Toor, MD (1)  ·  Andy Davies (1)  ·  Ann LaCasce, MD (1)  ·  Arturo Molina, MD (1)  ·  Ashley Rogers (1)

Results publications

PMID 34515338, PMID 21454450, PMID 30262660, PMID 15770833, PMID 17609424, PMID 20671118, PMID 23317527, PMID 23812930, PMID 23834234, PMID 24344220, PMID 24831981, PMID 25977584, PMID 26183076, PMID 26883583, PMID 27217449, PMID 29149611, PMID 31444250, PMID 31554370, PMID 33632155, PMID 33956213, PMID 36166003, PMID 36585130, PMID 37202143, PMID 37224793, PMID 37848259, PMID 38297229, PMID 39213421, PMID 39293083, PMID 39479329, PMID 39571113, PMID 39854647, PMID 39923848, PMID 39928957, PMID 40055982, PMID 40259519, PMID 40423982, PMID 40442628, PMID 41136989, PMID 42242517, PMID 42545812, PMID 42782312, PMID 42784255

NIH funding

2017 (3), 2016 (1), 2018 (1), 2019 (1), 2023 (1), P01CA015396 (1), P01CA111412 (1), P30CA012197 (1), R01CA226078 (1), R33CA226960 (1), UL1TR002240 (1)